FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1522374426> ?p ?o ?g. }

• W1522374426 endingPage "989" @default.
• W1522374426 startingPage "989" @default.
• W1522374426 abstract "Despite the increased use of rituximab therapy in neuromyelitis optica spectrum disorder (NMOSD), the overall efficacy and safety of long-term rituximab treatment in a large group of patients is uncertain. Furthermore, the identification of a predictor of rituximab response is an important issue for assessing the individual risk-benefit of therapy and making treatment decisions.To assess the long-term clinical efficacy and safety of rituximab treatment in patients with NMOSD and the influence of fragment c gamma receptor 3A (FCGR3A) polymorphisms on rituximab response.A retrospective review of 100 patients with relapsing NMOSD treated with rituximab for at least 6 months, from February 1, 2006, to January 31, 2015, at the institutional referral center. After induction therapy, a single infusion of rituximab (375 mg/m2) as maintenance therapy was administered whenever a reemergence of CD27+ memory B cells among peripheral blood mononuclear cells occurred. Using an allele-specific polymerase chain reaction-based method, the gene polymorphisms FCGR3A-V158F were assessed.The primary end point was annualized relapse rate; disability (Expanded Disability Status Scale score), safety of rituximab treatment, event of insufficient memory B-cell depletion following rituximab, and time to retreatment of rituximab were secondary end points.By January 31, 2015, a total of 100 patients received repeated rituximab treatment during a median of 67 months. Of these patients, 41 had more than 5 years' follow-up and 24 had more than 7 years' follow-up. The annualized relapse rate was reduced significantly by 96% (mean [SD] annualized relapse rate of prerituximab vs postrituximab, 2.4 [2.0] vs 0.1 [0.6]) and disability improved or stabilized in 96% of patients. Rates of adverse events were generally stable. The FCGR3A-F allele was associated with a risk of relapse while receiving rituximab treatment (additive model, P < .05; recessive model, P = .04; maximum, P = .03) and insufficient memory B-cell depletion (additive model, P = .03; recessive model, P = .03; maximum, P = .03).Repeated rituximab treatment for NMOSD was observed in an increasing number of patients and increasing duration of exposure and maintained good efficacy and a safety profile consistent with previous reports. The finding of a relationship between FCGR3A genetic polymorphisms and rituximab response suggests the importance of individualized rituximab treatment strategies in NMOSD." @default.
• W1522374426 created "2016-06-24" @default.
• W1522374426 creator A5008352226 @default.
• W1522374426 creator A5026159269 @default.
• W1522374426 creator A5028669492 @default.
• W1522374426 creator A5031522684 @default.
• W1522374426 creator A5042628215 @default.
• W1522374426 creator A5051308610 @default.
• W1522374426 creator A5062482182 @default.
• W1522374426 creator A5069350018 @default.
• W1522374426 creator A5079274190 @default.
• W1522374426 date "2015-09-01" @default.
• W1522374426 modified "2023-10-10" @default.
• W1522374426 title "Treatment Outcomes With Rituximab in 100 Patients With Neuromyelitis Optica" @default.
• W1522374426 cites W1823172479 @default.
• W1522374426 cites W1914229355 @default.
• W1522374426 cites W1965962344 @default.
• W1522374426 cites W1972241906 @default.
• W1522374426 cites W1991656907 @default.
• W1522374426 cites W2005365816 @default.
• W1522374426 cites W2012406069 @default.
• W1522374426 cites W2021279859 @default.
• W1522374426 cites W2029012161 @default.
• W1522374426 cites W2044360617 @default.
• W1522374426 cites W2079756029 @default.
• W1522374426 cites W2082237468 @default.
• W1522374426 cites W2087529564 @default.
• W1522374426 cites W2089363506 @default.
• W1522374426 cites W2095955743 @default.
• W1522374426 cites W2101185541 @default.
• W1522374426 cites W2107941546 @default.
• W1522374426 cites W2110718002 @default.
• W1522374426 cites W2130342500 @default.
• W1522374426 cites W2136132690 @default.
• W1522374426 cites W2147750230 @default.
• W1522374426 cites W2153301732 @default.
• W1522374426 cites W2155848385 @default.
• W1522374426 cites W2160264356 @default.
• W1522374426 cites W2162260323 @default.
• W1522374426 doi "https://doi.org/10.1001/jamaneurol.2015.1276" @default.
• W1522374426 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26167726" @default.
• W1522374426 hasPublicationYear "2015" @default.
• W1522374426 type Work @default.
• W1522374426 sameAs 1522374426 @default.
• W1522374426 citedByCount "150" @default.
• W1522374426 countsByYear W15223744262015 @default.
• W1522374426 countsByYear W15223744262016 @default.
• W1522374426 countsByYear W15223744262017 @default.
• W1522374426 countsByYear W15223744262018 @default.
• W1522374426 countsByYear W15223744262019 @default.
• W1522374426 countsByYear W15223744262020 @default.
• W1522374426 countsByYear W15223744262021 @default.
• W1522374426 countsByYear W15223744262022 @default.
• W1522374426 countsByYear W15223744262023 @default.
• W1522374426 crossrefType "journal-article" @default.
• W1522374426 hasAuthorship W1522374426A5008352226 @default.
• W1522374426 hasAuthorship W1522374426A5026159269 @default.
• W1522374426 hasAuthorship W1522374426A5028669492 @default.
• W1522374426 hasAuthorship W1522374426A5031522684 @default.
• W1522374426 hasAuthorship W1522374426A5042628215 @default.
• W1522374426 hasAuthorship W1522374426A5051308610 @default.
• W1522374426 hasAuthorship W1522374426A5062482182 @default.
• W1522374426 hasAuthorship W1522374426A5069350018 @default.
• W1522374426 hasAuthorship W1522374426A5079274190 @default.
• W1522374426 hasConcept C126322002 @default.
• W1522374426 hasConcept C143998085 @default.
• W1522374426 hasConcept C159654299 @default.
• W1522374426 hasConcept C167135981 @default.
• W1522374426 hasConcept C187212893 @default.
• W1522374426 hasConcept C203014093 @default.
• W1522374426 hasConcept C2779338263 @default.
• W1522374426 hasConcept C2780653079 @default.
• W1522374426 hasConcept C2781137167 @default.
• W1522374426 hasConcept C71924100 @default.
• W1522374426 hasConceptScore W1522374426C126322002 @default.
• W1522374426 hasConceptScore W1522374426C143998085 @default.
• W1522374426 hasConceptScore W1522374426C159654299 @default.
• W1522374426 hasConceptScore W1522374426C167135981 @default.
• W1522374426 hasConceptScore W1522374426C187212893 @default.
• W1522374426 hasConceptScore W1522374426C203014093 @default.
• W1522374426 hasConceptScore W1522374426C2779338263 @default.
• W1522374426 hasConceptScore W1522374426C2780653079 @default.
• W1522374426 hasConceptScore W1522374426C2781137167 @default.
• W1522374426 hasConceptScore W1522374426C71924100 @default.
• W1522374426 hasIssue "9" @default.
• W1522374426 hasLocation W15223744261 @default.
• W1522374426 hasLocation W15223744262 @default.
• W1522374426 hasOpenAccess W1522374426 @default.
• W1522374426 hasPrimaryLocation W15223744261 @default.
• W1522374426 hasRelatedWork W1491894218 @default.
• W1522374426 hasRelatedWork W1823172479 @default.
• W1522374426 hasRelatedWork W2014984186 @default.
• W1522374426 hasRelatedWork W2106308432 @default.
• W1522374426 hasRelatedWork W2185400242 @default.
• W1522374426 hasRelatedWork W2202764191 @default.
• W1522374426 hasRelatedWork W2327087261 @default.
• W1522374426 hasRelatedWork W2625404774 @default.
• W1522374426 hasRelatedWork W3132348878 @default.

• next